- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 28.01. | Lilly pens $1.1B pact with German biotech to work on gene editing med for hearing loss | ||
| 28.01. | Boehringer channels mid-stage momentum into pivotal kidney disease trial | ||
| 27.01. | After patient death, FDA lifts hold on 1 of 2 late-stage trials testing Intellia's CRISPR therapy | ||
| 27.01. | Lisata reclaims China rights to solid tumor candidate ahead of acquisition | ||
| 27.01. | From gene therapies to ... firearms? Italian biotech makes unexpected strategic pivot | ||
| 27.01. | Boehringer pens €1.05B deal for Simcere's preclinical IBD bispecific | ||
| 27.01. | Roche sees GLP1/GIP drug from Carmot produce 22.5% weight loss, readies phase 3 trial | ||
| 27.01. | Qilu programs path into cardiometabolic disease with $120M, AI-enabled Insilico alliance | ||
| 26.01. | European investment firm Gimv calls it quits on new life science financing | ||
| 26.01. | Ex-CytoDyn CEO sentenced to prison, must pay $5.3M restitution as former CRO leader wins new trial | ||
| 26.01. | Fortitude has faith molecular glue degraders can overcome ADC resistance | ||
| 26.01. | AstraZeneca keeps UK research site on pause, but options open | ||
| 23.01. | Sanofi plans global filings for key eczema prospect despite mixed phase 3 readout | ||
| 22.01. | Hoth strikes back against cancer drug skin toxicities, but share price stays frozen | ||
| 22.01. | Corxel secures $287M series D to fund phase 2/3 obesity studies of oral GLP-1 drug | ||
| 22.01. | Corcept racks up phase 3 cancer win to bounce back from FDA Cushing's rejection | ||
| 22.01. | BMS pens $850M solid tumor pact with T-cell engager biotech Janux | ||
| 21.01. | FDA outlines draft policy on MRD, complete response for accelerated approvals in multiple myeloma | ||
| 21.01. | Novo Nordisk offloads diabetes assets to Aspect amid cell therapy retreat | ||
| 21.01. | Cancer imaging company buys Lisata for phase 2-stage solid tumor drug | ||
| 21.01. | IO mulls more layoffs months after halving head count in wake of cancer vaccine setback | ||
| 21.01. | Insilico agrees on $66M deal to split rights for preclinical NLRP3 inhibitor with new Chinese biotech | ||
| 20.01. | Nkarta's CEO wore head-to-toe pink at JPM. Here's why it matters more than ever | ||
| 20.01. | Former Spero execs fined by SEC over antibiotic efficacy claims | ||
| 20.01. | Pfizer pens $530M deal to use Novavax's vaccine adjuvant tech on 2 programs |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.